Declaring Opioid Emergency, Trump Touts FDA Actions, NIH-Industry Partnerships

 
• By Brenda Sandburg
  
Generate a summary of this article
Listen to this article
Beta

Proclaiming the opioid epidemic a public health emergency, President points to FDA's prescriber training requirements and withdrawal of Opana ER; Sen. Leahy decries lack of additional funding.

Trump_Donald_160716_1200x675

At a standing room-only event in the East Room of the White House, President Donald Trump signed a memorandum declaring the opioid epidemic a public health emergency. The much-heralded announcement did not include specifics on how to combat the problem, but Trump pointed to recent actions by FDA and other government agencies as examples of what could be done under this policy.

Trump also did not indicate any additional funding would be provided to carry out initiatives, though he said he would...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from US FDA

PS-AgencyLeadership (Premium-1): Study Reveals How Immune System of Astronauts Breaks Down

Recent studies show that spaceflight can significantly weaken astronauts’ immune systems, making them more susceptible to infections and health complications during and after missions. Understanding these changes is crucial for ensuring the safety of future long-duration space travelers.

Nancy Test Circulable Section Geography

 
• By Brian Bossetta

This is a short description

New US FDA Adcomm Trend: Approved Cancer Meds Get Another Look When Competitors Coming

 
• By Sarah Karlin-Smith

Recent ODAC meetings suggest the FDA will expand focus beyond applications with pending approval decisions to refining trial designs and drug labels for competitors.

Califf: Not Wise To Create Problems Related to Chinese Pharma Supply Chain Dependence

 
• By Sarah Karlin-Smith

The US FDA Commissioner pushed for a rebalancing of the US’s pharmaceutical supply chains while also stressing that there is a role for US-China commerce that would be risky to compromise.

More from Agency Leadership

New US FDA Adcomm Trend: Approved Cancer Meds Get Another Look When Competitors Coming

 
• By Sarah Karlin-Smith

Recent ODAC meetings suggest the FDA will expand focus beyond applications with pending approval decisions to refining trial designs and drug labels for competitors.

Califf: Not Wise To Create Problems Related to Chinese Pharma Supply Chain Dependence

 
• By Sarah Karlin-Smith

The US FDA Commissioner pushed for a rebalancing of the US’s pharmaceutical supply chains while also stressing that there is a role for US-China commerce that would be risky to compromise.